For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Beta Pharma, Inc.

Calculating rank

USPTO Granted Patents = 17

% Expired Patents = 17.6

EPO Patents = 9

Trademarks = 3

Forward Citations = 17

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Don Zhang (17 out of 17 patents)

Jirong Peng (13 out of 13 patents)

Michael Nicholas Greco (12 out of 46 patents)

4. Michael John Costanzo (12 out of 12 patents)

5. Michael Alan Green (8 out of 23 patents)

6. Victoria Lynn Wilde (8 out of 8 patents)

7. Guojian Xie (4 out of 4 patents)

8. Yinxiang Wang (3 out of 15 patents)

9. Charles Davis (3 out of 3 patents)

10. Wei He (2 out of 124 patents)

11. Yunyan Hu (2 out of 15 patents)

12. Bin Han (2 out of 19 patents)

13. Wei Long (2 out of 20 patents)

14. Lieming Ding (2 out of 14 patents)

15. Fenlai Tan (2 out of 8 patents)

17 patents: Sort by Forward Citations

1. 12595246 - Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof (2026-04-07),

2. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),

3. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),

4. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),

5. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),

6. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),

7. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),

8. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),

9. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),

10. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),

11. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),

12. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),

13. 9820721 - Aspiration and biopsy needle apparatus and devices and applications thereof (2017-11-21),

14. 9359370 - Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof (2016-06-07),

15. 9163010 - Indolinone protein kinase inhibitors (2015-10-20),

Company Overview

Beta Pharma, Inc. is a biopharmaceutical company based in Wilmington, Delaware, specializing in the development and manufacturing of innovative therapies for various medical conditions. The organization focuses on advancing treatment options in oncology and other therapeutic areas, leveraging cutting-edge research and technology to address unmet medical needs. With a commitment to improving patient outcomes, Beta Pharma collaborates with healthcare professionals and institutions to bring novel solutions to market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

17 Patents

#237 in Wilmington, DE

#300 in Delaware

#18,927 in US

#36,017 in the World

Wilmington, DE, United States of America

Beta Pharma, Inc.

Forward Citations = 17

20 inventors:

Don Zhang (17 out of 17 patents)

Jirong Peng (13 out of 13 patents)

Michael Nicholas Greco (12 out of 46 patents)

4. Michael John Costanzo (12 out of 12 patents)

5. Michael Alan Green (8 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Beta Pharma, Inc.. Retrieved from https://idiyas.com/company/beta-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…